Axillary Hyperhidrosis
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Botanix PharmaceuticalsAustralia - West Perth
2 programs2
Sofpironium Bromide Gel, 15%Phase 31 trial
Sofpironium Bromide, 15%Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sound PharmaceuticalsVASER
Botanix PharmaceuticalsSofpironium Bromide, 15%
Botanix PharmaceuticalsSofpironium Bromide Gel, 15%
Clinical Trials (3)
Total enrollment: 714 patients across 3 trials
VASER Treatment of Axillary Hyperhidrosis/Bromidrosis
Start: Apr 2007Est. completion: Aug 200813 patients
Phase 4Completed
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Start: Dec 2020Est. completion: Aug 2021351 patients
Phase 3Completed
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Start: Oct 2020Est. completion: Jun 2021350 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.